Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

PowerPoint Presentation Financial Navigation: An Intervention for Reducing Cancer-Related Financial Toxicity in NC Oncology Care Settings Michelle L. Manning, MPH Deputy Director, Administration Comprehensive Cancer Support Program Lineberger Comprehensive Cancer Center Email: mmanning@unc.edu Learning Objective Use new knowledge to support cost-effective …
Acute-Promyelocytic-Leukemia-Cancer-Guide-2012
Matt Devino, MPH Director of Cancer Care Delivery & Health Policy Association of Community Cancer Centers Welcome and Opening Remarks @ACCCBuzz #ACCCORM CANCER PROGRAM LEADERSHIP Hospital Presidents CEOs, COOs, CMOs Vice Presidents Department Directors CLINICIANS Medical Radiation Surgical Pharmacy ADMINISTRATION Oncology Program and Practice …
Trends-in-Cancer-Programs-2014
MJ05-Innovations-in-Imaging
US Pharma Onco_Novartis Media and Investor Release Template.docx Novartis Pharmaceuticals Corp. US Communications East Hanover, NJ USA http://www.novartis.us https://twitter.com/novartisUS MEDIA & INVESTOR RELEASE Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14 • Tabrecta …
FAN-Full-Disclosure-Out-of-Pocket-Costs
Oncology-Nurse-Navigator
NEHOPS-2014
Sturm - Federal Health Policy_August 2018 Update_463588 Date Federal Health Policy: How It May Affect Your Program September 21, 2018 Association of Community Cancer Centers Oncology Reimbursement Meeting 1 Agenda 0100.015\463588(pptx)-E2 9-21-18 BackgroundI. Drug Pricing TrendsII. 340B Drug Pricing ProgramIII. Oncology Care Model (OCM)IV. New Reimbursement …
MA12-Social-Media-and-Your-Cancer-Program
DelRep-User-Manual
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. TACOS ONCOLOGY DRUG NEWSLETTER A P R I L 2 0 2 4 FDA APPROVALS Nivolumab (Opdivo) Nivolumab (Opdivo) plus cisplatin-based chemotherapy has been approved by the FDA for the treatment of patients with treatment-naive unresectable …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. TxSCO ONCOLOGY DRUG NEWSLETTER A P R I L 2 0 2 4 FDA APPROVALS Nivolumab (Opdivo) Nivolumab (Opdivo) plus cisplatin-based chemotherapy has been approved by the FDA for the treatment of patients with treatment-naive unresectable …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. NCOA ONCOLOGY DRUG NEWSLETTER A P R I L 2 0 2 4 FDA APPROVALS Nivolumab (Opdivo) Nivolumab (Opdivo) plus cisplatin-based chemotherapy has been approved by the FDA for the treatment of patients with treatment-naive unresectable …
- more - For immediate release Media Contact: May 15, 2018 Thomas Biegi O: +1 212-733-2204 E: Thomas.Biegi@pfizer.com Investor Contact: Ryan Crowe O: +1 212-733-8160 E: Ryan.Crowe@pfizer.com Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA - - - RETACRIT, the First U.S. Biosimilar …
surveys-administrators-2009
FAN-From-Coverage-to-Care-A-Roadmap-to-Better-Care-and-a-Healthier-You
BMT and Rehab CAR-T and Rehab Comprehensive Care of the Bone Marrow Transplant Patient Macy Hogan, PT, DPT Franciscan Health Objectives • To address special considerations for BMT patients to improve awareness, clinical reasoning, and standard of care when treating a BMT patient, particularly patients undergoing CAR-T therapy • To improve awareness of changes in the …
PATIENT PERCEPTIONS OF BIOMARKER TESTING A mixed-methods approach to understand the patient experience related to biomarker testing for NSCLC APPENDIX A: Patient Survey 1. To confirm, are you a 1. A lung cancer patient/survivor 2. Caregiver or former caregiver to a lung cancer patent TERMINATE 3. Neither TERMINATE 2. What is your age? ________ [PROGRAM OPEN END RANGE …